Is BioNexus Gene Lab Corp Common stock (BGLC) overvalued? · rev $9.5M
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
This page asks whether BioNexus Gene Lab Corp Common stock (BGLC) looks expensive on cached numbers — not a short thesis.
Latest reported BGLC revenue for 2024-12-31 was $9.5M. Net income was $1.6M. Revenue was down 2.7% from 2023-12-31 to 2024-12-31. BGLC currently screens at market cap $6.1M.
BGLC currently screens at market cap $6.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BGLC 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BGLC stock page for the full model, not this heading.
Not investment advice.